Endometrial cancer is a malignant tumor originating from the endometrial epithelium, one of the three major gynecological malignant tumors, with an increasing global incidence in recent years. The global annual new incidence is about 417,000 cases, with 97,000 deaths.
It is divided into two main types: Type I (estrogen-dependent, 80%–85% of cases), which is closely related to long-term estrogen stimulation, obesity, diabetes, and infertility, with well differentiation and good prognosis; Type II (non-estrogen-dependent, 10%–15% of cases), including serous carcinoma and clear cell carcinoma, with poor differentiation, high malignancy, and poor prognosis. The core symptom is abnormal vaginal bleeding, especially postmenopausal bleeding. Early endometrial cancer has a 5-year survival rate of over 90%, while advanced or recurrent cases have a poor prognosis.
China has the largest number of fertility-sparing treatment cases for early endometrial cancer in Asia, with a complete remission rate of over 85% for well-differentiated early-stage patients, and a postoperative live birth rate of over 50%, on par with top European and American centers. Top centers have original "progestin + hysteroscopic resection + adjuvant therapy" protocol to reduce recurrence rate.
The popularity rate of laparoscopic and robot-assisted minimally invasive surgery for endometrial cancer in top Chinese centers exceeds 90%, with a surgical success rate of over 99%. The 5-year overall survival rate of early-stage patients exceeds 95%, and the 5-year survival rate of locally advanced patients exceeds 70%, equal to top European and American centers.
PD-1/PD-L1 inhibitors, targeted drugs for advanced/recurrent endometrial cancer have been widely approved in China, fully synchronized with international guidelines, and covered by medical insurance, with an annual treatment cost of only 1/10–1/5 of that in the US. The molecular typing detection of endometrial cancer has a short cycle (7–14 days) and low cost, realizing precise personalized treatment.
The cost of minimally invasive radical surgery for endometrial cancer in top Chinese centers is only 7,000–10,000 USD, which is 1/5–1/3 of that in the US (40,000–60,000 USD). Surgery can be arranged within 1–2 weeks, while the waiting period in Europe and America is often 3–6 months.
Top centers provide complete long-term follow-up and postoperative rehabilitation management, including hormone replacement therapy for young patients after surgery, metabolic syndrome management, and integrated traditional Chinese and Western medicine treatment to improve quality of life and reduce recurrence risk.
